Cell & Gene

Harnessing The Power Of the Innate Immune System In Cancer Research https://lnkd.in/ejvvnXxw - By Sarah Cooley and Kyle Jensen, Sanofi While immunotherapies have transformed the cancer treatment landscape, the benefits have thus far been limited to a small number of patients with specific disease biologies or tumor types.

What Are Smart mRNAs? https://lnkd.in/ePn5SRb2 "We’re programing with the tools that evolution has given us. So, evolution has created all sorts of genetic regulatory elements and all sorts of ideas for how messenger RNA and DNA are processed – when genes turn on, when they turn off, and what we do is we use those genetic regulatory elements to achieve new ends." - Jacob Becraft, Strand Therapeutics

Quick reminder that Episode 79 of Cell & Gene: The Podcast featuring Strand Therapeutics' Jacob Becraft is available wherever you get your #podcasts. Episode 80, out on 7/4, will feature my conversation with Micah Benson, CSO at KSQ Therapeutics, Inc. We talk all about Tumor-Infiltrating Lymphocytes (TILs) have the potential to treat a variety of #solidtumor types. Benson explains KSQ's Phase 1/2 clinical study, KSQ-001EX, which consists of TILs in which the SOCS1 gene is inactivated by #CRISPR/Cas9 #geneediting. In addition to solid tumors, we address the therapeutic potential for #autoimmunedisease. Subscribe now so you never miss an episode! Thermo Fisher Scientific https://lnkd.in/enuX5Vei

Making Cancer Vaccines Is Complex; New Platform Guidance Could Help https://lnkd.in/e4mWMKaB The production of personalized therapies presents a very different manufacturing challenge compared to conventional therapeutic products.

In this edition of Cell & Gene "In Focus": TRENDING CONTENT - Catch Up  #1. What Does FDA's Draft Platform Guidance Mean For CGT Companies?  #2. New Report Solidifies Greater Philadelphia Region as Global CGT Leader  #3. New Guide Tackles Best Practices For Making Allogeneic Cell Therapies  #4. Viral Vector Based Gene Therapy Drug Products: Key Considerations For Choosing The Right Primary Container  #5. Cryopreservation Best Practices For Cell & Gene Therapy Source Material  #6. Top Strategies To Reduce Off-Target Effects For Safer Genome Editing

New 'WEE' Urgency Raised As FDA Requires DSCSA EDDS Interoperability https://lnkd.in/e7GyRttF - By Carl Accettura, Global Pharma Advisory This is the moment we’ve been waiting for: FDA is ending its yearlong enforcement discretion and expects companies to be compliant by Nov. 27.

CRISPR-Cas Genome Editing For Rejuvenation Of Aging Stem Cells https://lnkd.in/eBQgv5jH - By Jack Huang MD/PhD., CSTEAM-Biotech This technology offers promise for treating age-related diseases by improving the health and function of stem cells, thereby opening new therapeutic avenues and extending the quality of life of older adults.

In his most recent article, my colleague, Tyler Menichiello, talked to Siren Biotechnology's CEO, Nicole K. Paulk, PhD about how the #biotech is working to create a universal #AAV immuno-gene therapy that, much like the name implies, can be used “universally” to treat a variety of #solidtumor #cancer. Check it out. #cellandgenetherapy #cgt #genetherapy #oncology https://lnkd.in/ei9kQNaU

The Rising Tide Of Ophthalmologic Gene Therapies https://lnkd.in/es6Wswes In recent years, there’s been an increase in gene therapy clinical trials for inherited retinal diseases (IRDs) — a group of genetic conditions that can lead to vision loss and blindness.

mRNA Delivering Full-length Dystrophin for DMD https://lnkd.in/eXjtydMz Highlights, quotes, and more from the recently aired episode, "Developing an mRNA Therapy for DMD with Elixirgen Therapeutics, Inc.'s Aki Ko"